Communiqués ORBIS AG

Actions

OBS

DE0005228779

Services et conseils en informatique

Temps réel estimé Tradegate 13:17:29 14/08/2026			Varia. 5j.	Varia. 1 janv.
4,700 ^EUR	+0,86%		-1,69%	-19,66%

16/04	ORBIS AG annonce le versement d'un dividende annuel le 2 juin 2026	CI
30/03	Genmab : Orbis détient 4,99% des droits de vote au 27 mars	RE

Communiqués

28/05	General Meeting 2026: ORBIS reports a satisfactory fiscal year despite the generally challenging economic situation	PU
06/05	FedEx and Orbis Earn "Best of the Best" Halo Award: Delivering Sight Worldwide	AQ
26/03	ORBIS : reports satisfactory financial year despite the generally tense economic situation.	PU
15/01	FedEx Volunteer Pilot Sees Six-Year-Old Receive Sight	AQ
19/12	ORBIS : Change in management board of ORBIS SE as of 01.01.2026	PU
17/11	Pioneering Eye Health Partnership Doubles Sight-Saving Child Screenings in Zambian Province	AQ
03/09/25	Turkey slaps anti-dumping duties on thick-gauge rolled steel from South Korea	AQ
28/08/25	ORBIS : reports stable business performance in the first half of 2025	PU
04/08/25	Behind the Scenes: How FedEx Helps Keep the Flying Eye Hospital in the Sky	AQ
28/05/25	General Meeting 2025: ORBIS SE also profitable in financial year 2024 despite the economic crisis	PU
11/04/25	Orbis Protect Acquires Panthera Group Limited	AQ
03/04/25	UC Davis doctor trains pediatric anesthesiologists in country with critical shortage	AQ
28/03/25	ORBIS : Revenue and EBIT in financial year 2024 at previous year's level	PU
04/02/25	Helping Deliver Sight, Hope, and a Brighter Future: A Heartfelt Thank You to FedEx	AQ
07/01/25	Orbis Medicines Raises EUR 90 Million Series A Funding Round to Develop Pipeline of Oral Macrocycles	AQ
11/12/24	Creating an exceptional service experience: STADTWERK AM SEE introduces Microsoft Dynamics 365 with ORBIS	PU
09/10/24	Concentrated expertise on CRM and contract lifecycle management with Microsoft: ORBIS and CRMFIRST enter into a strategic partnership	PU
18/09/24	Orbis Medicines and Vivtex Form Research and Exclusive Licensing Collaboration to Support Orbis Development of Next-Generation Orally Dosable nCycles	AQ
14/08/24	ORBIS SE Adjustment of the outlook for the 2024 financial year	PU
29/05/24	Hauptversammlung 2024: ORBIS auch im Geschäftsjahr 2023 trotz Wirtschaftskrise mit profitablem Wachstum	PU
29/05/24	General Meeting 2024: ORBIS continues profitable growth in the 2023 financial year despite the economic crisis	PU
19/04/24	AGITATED SOLUTIONS RECEIVES HEALTH CANADA LICENSE FOR ORBIS MICROBUBBLE GENERATOR TO STREAMLINE CARDIAC BUBBLE STUDIES	AQ
08/04/24	New VR Solution to Democratize Ophthalmic Surgical Training: Affordable, Portable and Scalable	AQ
27/03/24	ORBIS : Profitable growth in financial year 2023	PU
20/03/24	ORBIS SE founds new subsidiary ORBIS Value Plus: Digital process transformation for business value optimization	PU